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Depression, apathy, and anhedonia are often comorbid in patients with Parkinson’s disease. Since the morbid states of apathy
and anhedonia are complicated, these symptoms are often diﬃcult to diagnose. Several therapeutic methods for apathy and
anhedonia are considered eﬀective. However, the validity of these methods has not been established. Similar to depression, apathy
and anhedonia clearly aﬀect the quality of life of patients and their families. Therefore, accurate diagnoses of morbid states in the
early stage of the disease and corresponding appropriate treatments should be given high priority.
1.Introduction
Parkinson’s disease (PD) is a progressive degenerative disease
related to the extrapyramidal system. Patients with this
disease show four major symptoms: resting tremor, muscle
rigidity, akinesia, and postural reﬂex disturbance, all of
which show a gradual progression. The prevalencerate of PD
is300casesper100,000.AlthoughPDisobservedoverawide
age range, its crisis and prevalence rates generally increase
with age. In Japan, the number of PD patients is increasing
with the aging of the society. Although the primary cause
of PD is the degeneration of the dopamine secretory cells
in the mesencephalon substantia nigra pars compacta, the
other major causative factors include the degeneration and
disappearance of neurons in the noradrenaline system (locus
coeruleus), the serotonin system (dorsal raphe nucleus), and
the acetylcholine system (basal ganglion of Meynert). As
a result, PD patients show various disorders in the motor
and nonmotor systems. There has been increasing interest
in PD nonmotor symptoms (NMSs). NMSs include various
disorders such as mood disorders, cognitive dysfunction,
mental symptoms, autonomic nervous system disorders, and
perception disorders. These NMSs can be evident in the
progressive stage, as well as in the early stages of functional
nonmotor disorders related to cognitive, emotional, and
behavioral aspects. Therefore, early detection and diagno-
sis of NMS are important for preventive therapies [1].
Regarding mood disorders presenting as NMS, depression
[2], apathy [3], and anhedonia [4] complicate PD and
are present at high rates in PD patients (approximately
40%), although these rates diﬀer among the various reports.
Thesecomplicationsareimportantfactorsthatdetrimentally
aﬀect the patients’ quality of life and care burden [5].
Although apathy and anhedonia are often confused with
depression, they diﬀer from depression in terms of mech-
anisms, therapeutic approaches, and prognoses. If therapy
is desultorily performed due to misdiagnosis, recovery from
the primary disease may be delayed, activities of daily living
may decrease, and the morbid states may worsen. Therefore,
correct diﬀerential diagnosis is essential.
Inthepresentstudywedescribetheresultsobtainedfrom
our assessments of apathy and anhedonia occurring along
with PD.
2. Deﬁnition andMorbid Stateof Apathy
2.1. The Relationship of Apathy with Depression. Depres-
sion is diagnosed on the basis of the diagnostic criteria
deﬁned in the Diagnostic and Statistical Manual of Mental
Disorders-Fourth Edition (DSM-IV) (Table 1)[ 6]. Apathy
is a state in which only decreased willingness is noticeable,
while depressed mood and a feeling of tragedy, which are
characteristic of depression, are not observed, and emotional
bias is not recognized [7]. Therefore, apathy is not deﬁned2 ISRN Neurology
Table 1: DSM-IV criteria of major depression.
Items
(1) Depressed mood
(2) Loss of interest or loss of pleasure
(3) Signiﬁcant weight loss or loss of appetite
(4) Insomnia or hypersomnia
(5) Psychomotor agitation or retardation
(6) Fatigue or loss of energy
(7) Feelings of worthlessness or excessive or inappropriate
guilt
(8) Diminished ability to think or concentrate, or
indecisiveness
(9) Suicide attempt or a speciﬁc plan for committing
suicide
in the DSM-IV (if apathy is forcibly expressed, it can be
considered as a state in which only the ﬁrst half of “loss
of interest or loss of pleasure” in Table 1, that is, “loss
of interest,” exists). Among general physical diseases, PD
is widely recognized as a disease that is easily complicated
with depression. James Parkinson, who ﬁrst reported PD
in his “Essay on shaking palsy,” observed that it is often
complicated by depression in addition to motor symptoms
[8].
There are varying forms of depression in PD, and these
forms show widely varying rates of occurrence.Reijnders et
al. (2008) [9] analyzed 104 papers and reported that the
least and greatest values of the prevalence rate of depression
occurring along with PD are 2.7% and 89%, respectively.
The prevalence rate of depression occurring along with
PD was believed to vary because the evaluation methods,
judgment criteria, and sampling methods varied in diﬀerent
studies [10]. However, the prevalence rate of depression
occurring along with PD varied largely even in cases where
the population and examinationmethods were similar to
each other, as shown in Table 2. These results reﬂect the
multiplicity of depression occurring along with PD.
Only 2.4% (2.2%–7.6%) of the cases showing depression
along with PD satisfy the criteria for major depression.
This value is almost equal to the prevalence rate of major
depressioninthegeneralpopulation[11].Therefore,depres-
sion occurring along with PD should be recognized as
minordepression,ordysthymia,insteadofmajordepression.
Recently, Ehrt et al. [12] compared PD patients with depres-
sion to similarly aged depression patients without PD. All
depression patients without PD were diagnosed with major
depression, and 1/4 of the PD patients with depression were
diagnosed with major depression. Moreover, the incidences
of“depressivemood,”“feelingofguilt,”and“lossofpleasure”
were signiﬁcantly higher in depression patients without PD,
and the incidence of “loss of concentration” was signiﬁcantly
higher in PD patients with depression. These results agree
with previous ﬁndings which suggest that apathy is readily
evident and that feelings of guilt, suicide attempts, and
depressed mood are milder in PD patients with depression
than in patients with endogenous major depression [13].
Thus, apathy in combination with PD explicitly expresses
one of the pathological characteristics of depression in PD.
2.2.TheConceptThatApathyandDepressionAreIndependent
Morbid States. Starkstein, a researcher who proposed apathy
as a disease, pointed out the following diagnostic criteria
for apathy: A1, a decrease in goal-directed behavior; A2,
a decrease in goal-directed cognition; A3, an emotional
deﬁcit associated with goal-directed behavior [3]. Based
on the results obtained by studies on brain damage and
cerebrovascular accidents, apathy is reported to be caused by
damage to the dorsolateral prefrontal cortex, basal ganglion,
orbital region, internal capsule (posterior limb), or the
thalamus [14]. The frequency of occurrence of apathy is the
highestwhenthefrontallobeisdamaged.Thereisa60%and
higher probability of complication by apathy in patients with
progressive-stage Alzheimer’s disease [15, 16], although this
ﬁgure varies widely among reports.
The frequency of apathy occurrence is the secondly
higherwhenthebasalganglionisdamaged.Basalgangliadis-
eases, such as PD, progressive supranuclear palsy, and Hunt-
ington’s chorea, are complicated by apathy in approximately
40% of the cases [7, 17]. In patients with PD, abnormalities
in the orbitofrontal area, such as the cingulate gyrus, the
corpus striatum, and the frontal lobe circuit (which plays
an important role in proﬁt-sharing-based reinforcement
learning), and the mesocortical dopamine system result in
motivational disorders such as apathy [18].
Symptoms common to apathy and depression include
loss of interest, or loss of pleasure, retardation, fatigue,
decreased emotional reactions, indiﬀerence, social degener-
ation, decreased initiation, decreased persistence, and loss
of insight, and hypersomnia. Symptoms observed only
in depression include depressed mood, suicidality, self-
condemnation, excessive or inappropriate guilt, feelings of
despair, and loss of appetite [19]. Apathy is a common
phenotype of major depression. However, apathy syndrome,
inwhichremarkableapathyisobserved,isadiﬀerentmorbid
state that occurs over an extended period. Depression is
g e n e r a l l yc o n s i d e r e da n“ a ﬀective (emotional) disorder”
accompanied by pathos. However, apathy is considered a
“motivational disorder” and is not accompanied by aﬀective
disorders [20]. Unlike the ﬁndings in depression, emotion is
ﬂattened and no pathos is observed in apathy.
Recently, Kirsch-Darrow et al. [21] evaluated depression
and apathy in PD by using dystonia as a control. They found
cases of PD and dystonia that were similarly complicated
by apathy and depression. However, independent apathy
development was observed at a high rate in PD patients only.
Therefore, they concluded that apathy is the core feature of
PD, and it can occur without depression, because apathy is a
symptom that is independent of depression.
2.3. Diagnosis and Evaluation Methods of Apathy. Apathy
evaluation methods can be roughly classiﬁed into subjective
evaluation methods, which are based on self-recording sys-
tems, and objective evaluation methods, which are based on
interviews (observation). The former is suitable for patientsISRN Neurology 3
Table 2: Values of the prevalence rate of depression occurring along with PD.
Author n Depressed state Major depression Dysthymia
1986 Santamaria 34 32.3 2.9 29.4
1988 Mayeux 339 47
1990 Brown 40 25
2000 Cubo 88 7.3 7.3
2000 Goladi 172 33
2003 Krishnan 126 12.7
1995 Tison 60 32.7
2001 Happe 56 76.4
2001 Shulman 99 36
2002 Happe 116 37.1
2002 Marinus 177 38.4
2002 Shilman 101 44
2003 Roji 353 56.9
2005 Hely 52 53.6
2005 Holroyd 100 15
2005 Prado 60 38.3
2006 Kirsch-Darrow 80 26.3
2006 Weintraub 130 36.2
with mild to moderate apathy. The Apathy Evaluation Scale
(AES) [22] and the Apathy Scale (AS) [3]c a nb eu s e df o r
subjective evaluation. AES consists of 18 items and was
created by Marin et al. [22]. Starkstein et al. [3]c r e a t e d
AS by amending AES to reduce the number of items to
14, and thereby making the scale easier to use for PD
patients. Furthermore, AS is extensively used worldwide. In
the English and Japanese versions, 14 and 16 cut-oﬀ points,
respectively, are set [23]. Moreover, the validity of AS has
already been established. AS is an evaluation scale based
on a self-recording system; patients whose spontaneity is
remarkably low and those with advanced dementia cannot
answer the questions, which may limit the use of AS.
In2006,Sockeeletal.[24]createdtheLilleApathyRating
Scale (LARS). Although LARS consists of 33 items, most
of these items adopt the structured interview form with a
choice between “Yes” or “No.” Therefore, LARS can be used
to evaluate patients who are capable of conversing. In2011,
Mulin et al. [25] examined the clinical validity of LARS for
PD. LARS was recommended to be used with AS for PD.
LARS and AS should be used depending on the purpose of
the evaluation.
2.4. Examination Results Obtained in Our Institute—Part 1:
Depression and Apathy. The prevalence rates of depression
and apathy in PD and the depression characteristics were
examined using multiple controls.
2.4.1. Subjects. The PD group consisted of 46 PD patients
(Table 3), and the three control groups consisted of 54
patients with acute-phase stroke (stroke group), 20 patients
with medication-overuse headache (MOH; MOH group),
and 10 patients with endogenous depression (endogenous
depression group). The age and sex of the PD group patients
were similar to those of the patients in the control groups.
Table 3 shows the details of each group.
2.4.2. Methods. The patients in each group were diagnosed
using the diagnostic criteria deﬁned in the DSM-IV. The
levels of depression were categorized as major depression,
minor depression, or dysthymia. The Hamilton Depression
Scale, which is comprised of 17 items (HAM-D17)[ 26],
was also used to assess the patients. Using the Japanese
version [23] to determine the apathy score, we diagnosed
the existence of apathy in each group. Based on the results,
the prevalence rate of mood disorders in each group was
calculated, and the complication rates of depression and
apathy in each group were investigated. Subsequently, using
subgroups of patients who were diagnosed with depression,
a subanalysis was performed on nine low-ranked items of
the 17 items in the HAM-D17; in this subanalysis, ﬁve-grade
evaluation was performed to investigate the characteristics of
mood disorders in PD. The Wilcoxon signed-rank test was
used for the low-ranked item subanalysis in the HAM-D17
in PD. Furthermore, the Mann-Whitney’s U test was used to
compare items in the PD group with those in each control
group.
2.4.3. Results
(A) Prevalence Rates of Depression and Apathy. Table 4 shows
the depression and apathy prevalence rates. The depression
prevalence rate in the PD group was 19.6%, and this rate
was almost equal to that in the stroke group. The apathy
prevalence rate in the PD group was as high as 50%,
and this rate was much higher than those in the control
groups.Moreover,88.9%ofPDpatientswhowerediagnosed4 ISRN Neurology
Table 3: Materials of examination 1. mRS: modiﬁed Ranking Scale.
n Male Female Mean age ± SD
(year) Other conditions
PD 46 16 30 64.6 ±10.5
Duration from onset 60 ± 48.6S D
(month) Hoehn and Yahr scale I: 1 II: 5
III: 29 IV: 11 treated; 32 not treated: 14
Stroke 54 19 35 66.5 ±10.6
Duration from onset:17.9 ±4.9S D( d a y )
m R SG r a d e0:5G r a d e1:1 4G r a d e2:1 5
Grade 3:12 Grade 4:8
MOH 20 7 13 41.6 ±15.7 All treated
Endogenous
depression 10 4 6 52.0 ±22.6 All not treated
Table 4: Result A of examination 1. Prevalence of mood disorders
in PD and control groups.
n Depression
(major depression) Apathy Apathy/depression
PD 46 19.6% (6.5%) 50.0% 88.9%
Stroke 54 18.5% (1.8%) 35.2% 50.0%
MOH 20 65.0% (20.0%) 35.0% 46.0%
with depression also had apathy, with a complication rate
remarkably higher than those of the other groups.
(B) Subanalysis of Nine Low-Ranked Items of the HAM-D17
in the PD Group. Table 5 shows the average score ± SD of
eachoftheninelow-rankeditemsoftheHAM-D17 inthePD
group and the three control groups. Figure 1 shows a graph
oftheaveragePDgroupscores.Amongthenineitems,“work
andinterests”obtainedthehighestaveragescore,followedby
“anxiety, psychic.” No signiﬁcant diﬀerence was observed in
the average score between these two items in the signed-rank
test. However, the average scores of the other seven items,
such as “depressed mood,” were signiﬁcantly lower than that
of “work and interests.”
(C) Comparison of the PD Group with the Control Groups
(Stroke, MOH, and Endogenous Depression). The average
scores of the HAM-D17 items “depressed mood,” “retarda-
tion,” and “agitation” were signiﬁcantly lower in the PD
group than in the endogenous depression group (Table 5).
Particularly, the average score of the item “depressed mood”
was lower in the PD group than in three control groups. In
contrast, the average scores of the item “work and interests”
and items that reﬂected anxiety in the PD group were similar
to those in the endogenous depression group.
2.4.4. Discussion. The results in Section 2.4.3 (A) show that
the prevalence rate of apathy is much higher in the PD
group than in the control groups. This ﬁnding supports the
results reported by Kirsch-Darrow et al. [21], who described
that apathy is the core feature of PD. The complication
rate of depression and apathy described in Section 2.4.3
(A) and the results described in Section 2.4.3 (B) and (C)
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Figure 1 :R e s u l tBo fe x a m i n a t i o n2 - 2 .C h a r a c t e ro fd e p r e s s i o ni n
PD. n.s. P<. 05 (Wilcoxon signed-rank test).
supportthehypothesisthatinPDpatientsapathyisgenerally
and frequently observed, even in the state of depression.
Section 2.4.3 (C) shows that no signiﬁcant diﬀerence was
observedintheaveragescoreof“workandinterests”between
the PD group and endogenous depression group, and
Section 2.4.3 (B) describes that a signiﬁcant diﬀerence was
observed in the average score between “work and interests”
and“depressedmood,”“feelingofguilt,”and“suicide.”These
results indicate that in PD patients with depression the
frequencies of decreased willingness and loss of pleasure are
higher,andthefrequenciesoffeelingofguilt,self-accusation,
and feeling of loss are lower, and also the rate of suicide is
lower than in patients with “endogenous depression.” [13]
Similar to depression and apathy, PD is typically ac-
companied by anxiety disorders, which are observed in
approximately 40% of PD patients [3], although this rate
diﬀers among various reports. Anxiety disorders are caused
by decreased serotonin following dorsal raphe nucleus
denaturation due to PD progression, or by overactivity of
the noradrenaline system caused by the disinhibition ofISRN Neurology 5
Table 5: Result B of examination 2-1. Diﬀerences between PD and control groups in HAM-D17 subitems. P<. 05 Mann-Whitney U test.
Items PD Stroke MOH Endogenous depression
1 Depressed mood 1.44 ±1.13∗ 1.78 ±1.09∗ 2.08 ±1.04 2.78 ±0.67
2 Feeling guilt 0.78 ±0.67 0.56 ±0.73 1.31 ±1.11 1.11 ±0.93
3 Suicide 0.44 ±0.53 0.44 ±0.73 0.92 ±1.04 1.56 ±1.51
7 Work and interests 2.56 ±1.01 1.44 ±0.73∗ 2.23 ±0.80 2.44 ±1.01
8 Retardation 0.11 ±0.33∗ 0.56 ±0.73 0.31 ±0.50∗ 0.89 ±0.78
9 Agitation 0.00∗ 0.33 ±0.50 0.31 ±0.50∗ 0.44 ±0.53
10 Anxiety, psychic 2.22 ±0.97 1.67 ±1.12 2.31 ±1.20 2.44 ±0.88
11 Anxiety, somatic 1.56 ±1.01 1.67 ±0.87 2.46 ±0.90 1.44 ±0.53
15 Hypochondriasis 1.22 ±0.67 1.44 ±0.88 1.15 ±1.14 1.56 ±0.88
Table 6: Materials of examination 2.
Sex Male: 27 Female: 23
Mean age (year) 67.8 ±11.7( S D )
Duration from onset (year) 8.1 ±5.4( S D )
Hoehn-Yahr scale II: 8, III: 31, IV: 11
Treatment Treated: 46 Not treated: 4
the dopamine nerve to the locus coeruleus. In this study, we
did not diagnose anxiety disorders in accordance with the
DSM-IV, and therefore, the detailed mechanism of anxiety
disorders is unknown. However, the results related to anxiety
in (C) suggest that similar to depression in PD, anxiety
disorders can also become a complication in PD.
3.Deﬁnition andMorbidState of Anhedonia
3.1. Apathy and Anhedonia. Similar to apathy, anhedonia [4]
has recently attracted attention as an NMS in PD. Apathy
is mainly characterized by loss of primary motivation,
loss of interest in the environment, and aﬀective dullness.
Anhedonia is the state in which the patient cannot derive
essential pleasures from behaviors and activities that were
joyfully performed in the past. In other words, anhedonia is
a morbid state in which the patient’s sensitivity to pleasure
has decreased. Similar to apathy, anhedonia is not deﬁned
in the DSM-IV. If anhedonia is forcibly expressed, it is the
state in which only “loss of pleasure” is manifest, but not
“loss of interest” as shown in Table 1. Anhedonia in PD can
be explained as follows: (a) disturbance of the dopaminergic
circuit, which projects dopamine from the mesolimbic
system to the frontal cortex, aﬀecting the reward system in
the neurodegenerative process; (b) decreased motivation; (c)
decreasedwillingness,decreasedspontaneity,lossofsociality,
and loss of interest in joyful stimuli (sexual acts, eating,
smoking, drinking, etc.) [4, 26].
As mentioned above, anhedonia has nearly the same
meaning as “loss of pleasure” in the diagnostic criteria of
major depression in the DSM-IV. Among symptoms that
have been reported as anhedonia in PD, decreased willing-
ness and emotional disorders are also observed in apathy.
Moreover, the mechanism, which is assumed to be a reward-
system disturbance in the dopamine system, is common to
apathy and anhedonia. Lemke et al. [4]c o n d u c t e da no p e n
study to evaluate the eﬀect of pramipexole and reported that
anhedonia was observed in 45.7% of the 626 PD patients
involved in the study. This value is similar to the apathy
prevalence rate (approximately 40%) [3].
The relationship between apathy and anhedonia in PD
has not been explained in detail. Pluck and Brown [27]
investigated apathy in 45 PD patients and reported that
in cases where apathy was clearly observed, anhedonia was
also signiﬁcantly present. Moreover, no relationship between
apathy and depression was observed. Therefore, apathy and
anhedonia are considered to have similar mechanisms and
morbid states.
To evaluate anhedonia, the Snaith-Hamilton Pleasure
Scale (SHAPS), created by Snaith et al., can be used [28].
SHAPS uses a self-recording system and consists of 14 ques-
tion items. Since these items are scarcely aﬀected by motor
functions, SHAPS can be used to evaluate anhedonia in PD
patients. Unlike AS, SHAPS cannot diagnose anhedonia on a
stand-alone basis (anhedonia is “suspected” when the score
is 3 or higher). However, SHAPS is useful in determining
the eﬀects of therapy. The study conducted by Lemke et al.
employed SHAPS.
3.2. Examination Results Obtained in Our Institute—Part
2: Apathy and Anhedonia. The relationship between the
morbid states of apathy and anhedonia in PD was examined.
3.2.1. Subjects. In this examination 50 PD patients were used
as subjects ( Tables 5 and 6).
3.2.2. Methods. Using diagnostic criteria deﬁned in the
DSM-IV we diagnosed depression (major depression, minor
depression, or dysthymia). Moreover, using the AS Japanese
version [23] and SHAPS, apathy and “suspected” anhe-
donia were diagnosed and quantiﬁed. Prevalence rates of
depression, apathy, and anhedonia were calculated, and
their complication rates were investigated. The correlation
between AS and SHAPS was evaluated using the Spearman’s
correlation coeﬃcient by rank test.6 ISRN Neurology
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Figure 2: Result A of examination 2. Prevalence of apathy, anhedonia, and depression in PD.
0
5
10
15
20
25
30
35
40
0 5 10 15 20 25 30 35
S
A
H
A
P
S
(
a
n
h
e
d
o
n
i
a
)
AS (apathy)
Figure 3: Result B of examination 2. Correlation between apathy
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Figure 4: Relationship of apathy, anhedonia, and depression.
3.2.3. Results
(A) Prevalence Rate. Prevalence rates of depression, apathy
(AS ≥ 16), and “suspected anhedonia” (SHAPS ≥ 3) were
18%, 44%, and 74%, respectively. As shown in Figure 2,
nearly all cases diagnosed with depression were complicated
with apathy and anhedonia, and nearly all cases diagnosed
with apathy were complicated with anhedonia.
(B) Relationship between Apathy and Anhedonia. Figure 3
shows the correlation between AS (apathy) and SHAPS
(anhedonia). As shown in this ﬁgure, a strong correlation
(r = 0.64 and P = .00000065) was obtained between AS and
SHAPS.
3.2.4. Discussion. The prevalence rates of depression and
apathy are similar to those in the examination results from
part 1. The prevalence rate of “suspected anhedonia” was
signiﬁcantly higher than that in the report by Lemke et
al. Since SHAPS was used in the present study and had
been translated into Japanese by the author of this paper
and since the validity of SHAPS in Japanese has not been
established, the prevalence rate of “suspected anhedonia”
maybeoverestimated.However,nearlyallpatientsdiagnosed
with “suspected” anhedonia were also diagnosed with apa-
thy. Moreover, a strong correlation was obtained between
AS and SHAPS, as described in (B). Therefore, apathy
and anhedonia share a common mechanism (dopamine
exhaustion disturbances of the reward system). Thus, apathy
and anhedonia are core features of mood disorders in PD
and are independent of depression in Japanese patients.
Figure 4 shows an approximate relationship between apathy,
anhedonia, and depression in PD.
4. Therapy for Apathy and
Anhedonia (Pharmacotherapy)
At present, there are no proven medicines for apathy and
anhedonia in PD, and the suitability of PD therapy for
treating apathy and anhedonia needs to be evaluated. When
PDisstronglysuspectedtobecausedbydopaminedeﬁciency
(e.g., therapy has been extremely insuﬃcient, or apathy
or anhedonia appears only in the oﬀ stage), dopaminergic
therapy may be eﬀective. In particular, pramipexole, a
dopamine agonist, is reported to improve the symptoms of
depression and decreased willingness. However, such results
were mainly obtained in open studies, and the therapeutic
methods diﬀer according to the opinions of specialists. Addi-
tional dopaminergic therapy in patients who show suﬃcientISRN Neurology 7
control over motor symptoms may increase the risk of
inducing adverse eﬀects, such as lower limb edema, daytime
drowsiness, valvular disease of the heart, mental symptoms,
and dyskinesia. Therefore, the so-called “made to order ther-
apy”inconsiderationofthepatient’sbackgroundisessential.
4.1. Dopaminergic Therapy. Apathy or anhedonia in PD
exhibits similar symptoms to subcortical dementia, in which
the motivational disorder caused by a disturbance in the
dopamine projection system of the mesencephalon frontal
cortex plays a central role [1]. If true, dopaminergic therapy
should be the ﬁrst choice to treat apathy and anhedonia
in PD patients. Among dopamine agonists, pramipexole,
pergolide, and ropinirole are reported to be eﬀective in
treating decreased willingness and depression in many cases
[29]. Particularly, pramipexole has a stimulatory action on
D2 receptors in the nigrostriatal dopamine system related
to the motor system and D3 receptors. D3 receptors are
widely distributed in the mesolimbic pathway (from the
ventral mesencephalon to the nucleus accumbens) and
the amygdaloid body in the dopamine projection system
in the mesencephalon frontal cortex. The D3 stimulatory
action of pramipexole in these emotion-related sites is
presumed to improve symptoms of apathy and anhedonia
[30]. There have been several large-scale open studies on
anhedonia.Reichmann et al. [26] administered pramipexole
to 135 anhedonia patients, and Lemake et al. [4] adminis-
tered pramipexole to 286 PD patients with anhedonia. In
these patients, anhedonia signiﬁcantly improved in addition
to motor symptoms. In 2010,Bxarone et al. [31]r e p o r t e d
that pramipexole is eﬀective for treating depression in PD.
Because a randomized double-blind method was adopted,
the conﬁdence level of the obtained results was high.
Several reports have described that selegiline, a
monoamine oxidase B (MAO-B) inhibitor, is eﬀective for the
treatment of decreased willingness and depressed mood in
PD.Tom and Cummings [32] recommended selegiline as the
ﬁrst choice to treat depression in PD patients not exhibiting
suicidality. The primary eﬀects of selegiline are inhibition
of MAO-B and eﬃcient use of intracranial dopamine.
Moreover, selegiline is known to reinforce the intracranial
phenylethylamine (PEA) activity [33]. PEA promotes
serotonin release to improve symptoms of decreased
willingness and depressed mood in PD. Therefore, PEA is
particularly eﬀective for apathy and anhedonia complicated
with depression. Unlike dopamine agonists that are typically
used alone, selegiline can be used in combination with other
medicines, that is, the so-called “add-on use” is possible.
Therefore, selegiline is a simple and convenient drug.
However, since selegiline used in combination with antide-
pressants (which are described below) is contraindicated,
care must be taken when administering selegiline.
Since amantadine hydrochloride induces dopamine sec-
retion and exhibits a catecholamine stimulatory action, this
medicine is useful to treat PD. Because of its mechanism, the
eﬀect of amantadine hydrochloride on apathy is expected.
Amantadine hydrochloride is used to treat apathy in PD as
a supplemental therapy [34].
4.2. Antidepressants. Few reports exist on the eﬀects of
various antidepressants on apathy in PD (without depres-
sion). Selective serotonin reuptake inhibitors (SSRIs), sero-
tonin noradrenaline reuptake inhibitors (SNRIs), tricyclic
antidepressants (TCAs), and tetracyclic antidepressants were
reported to be eﬀective therapies for major depression
occurring along with PD. In particular, the eﬀect of the
TCA nortriptyline [35]w a sr e p o r t e dt ob ee ﬀective in a ran-
domized controlled trial with a placebo group. The positive
eﬀects of the SSRIs sertraline [36] and paroxetine [37]o n
depression in PD patients were reported in open studies
based on more than 100 cases. The American Academy of
Neurology (ANN) recommends amitriptyline for the treat-
ment of depression in PD [38]. These results were obtained
on the basis of depression, not apathy or anhedonia alone.
Generally, antidepressants are not eﬀective for the treatment
of depression in which remarkable decrease in willingness is
observed. On rare occasions, antidepressants worsened the
decreased willingness [39]. Thus, antidepressants should not
be imprudently used for cases where apathy or anhedonia is
independently observed. Maruyama [40] administered mil-
nacipran, an SNRI, to eight PD patients with depression and
reportedthatitwaseﬀectiveintreatingdepressiondistinctive
to PD, including cases where signiﬁcant apathy or anhedonia
was observed. Moreover, milnacipran administration caused
total remission in cases of depression with PD for which an
SSRI was not eﬀective [41]. According to the monoamine
hypothesis, SNRIs, which have signiﬁcant noradrenaline-
inducing activity, are eﬀective fordepression in which apathy
or decreased willingness is remarkably signiﬁcant [42]. Since
the eﬀects of SNRIs on depression and decreased willingness
areexpectedincasesforwhichpramipexoleisnotsuﬃciently
eﬀective, the validity of SNRIs must be established.
5. Conclusion
Together with depression, apathy and anhedonia often
develop in patients with PD. Since the morbid states of
apathy and anhedonia are complicated, these symptoms are
often diﬃcult to diagnose. Several therapeutic methods for
apathy and anhedonia are considered eﬀective. However,
the validity of these methods has not been established.
Similar to depression, apathy and anhedonia clearly aﬀect
the quality of life of patients and their families. Therefore,
accurate diagnoses of morbid states in the early stage of the
disease and corresponding appropriate treatments are more
important than ever.
References
[1] E. C. Wolters, “Intrinsic and extrinsic psychosis in Parkinson’s
disease,” Journal of Neurology, vol. 248, supplement 3, pp. 22–
27, 2001.
[2] J. L. Cummings, “Depression and Parkinson’s disease: a
review,” American Journal of Psychiatry, vol. 149, no. 4, pp.
443–454, 1992.
[3] S. E. Starkstein, H. S. Mayberg, T. J. Preziosi, P. Andrezejewski,
R. Leiguarda, and R. G. Robinson, “Reliability, validity, and
clinical correlates of apathy in Parkinson’s disease,” Journal of8 ISRN Neurology
Neuropsychiatry and Clinical Neurosciences, vol. 4, no. 2, pp.
134–139, 1992.
[ 4 ]M .R .L e m k e ,H .M .B r e c h t ,J .K o e s t e r ,a n dH .R e i c h m a n n ,
“Eﬀects of the dopamine agonist pramipexole on depression,
anhedonia and motor functioning in Parkinson’s disease,”
Journal of the Neurological Sciences, vol. 248, no. 1-2, pp. 266–
270, 2006.
[ 5 ] K .K .H e r l o f s o n ,P .L .J a n ,T .E l i s ,a n dJ .G .M æ l a n d ,“ I n ﬂ u e n c e
of clinical and demographic variables on quality of life
in patients with Parkinson’s disease,” Journal of Neurology
Neurosurgery and Psychiatry, vol. 66, no. 4, pp. 431–435, 1999.
[6] American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders, American Psychiatric Associa-
tion, Washington, DC, USA, 4th edition, 1994.
[7] R. S. Marin, “Apathy: a neuropsychiatric syndrome,” Journal
of Neuropsychiatry and Clinical Neurosciences,v o l .3 ,n o .3 ,p p .
243–254, 1991.
[8] J. Parkinson, An Essay on the Shaking Palsy, Whittingham and
Rowland for Sherwood, Neely and Jones, London, UK, 1817.
[9] J. S. Reijnders, U. Ehrt, W. E. Weber, D. Aarsland, and A.
F. Leentjens, “A systematic review of prevalence studies of
depression in Parkinson’s disease,” Movement Disorders, vol.
23, no. 2, pp. 183–189, 2008.
[ 1 0 ]C .V e a z e y ,S .O .A k i ,K .F .C o o k ,E .C .L a i ,a n dM .E .
Kunik,“PrevalenceandtreatmentofdepressioninParkinson’s
disease,” Journal of Neuropsychiatry and Clinical Neurosciences,
vol. 17, no. 3, pp. 310–323, 2005.
[11] K. Yamamoto, “Depression in Parkinson’s disease: its preva-
lence, diagnosis, and neurochemical background,” Journal of
Neurology, vol. 248, no. 3, pp. 5–11, 2001.
[12] U. Ehrt, K. Bronnick, A. F. Leentjens, J. P. Larsen, and
D. Aarsland, “Depressive symptom proﬁle in Parkinson’s
disease: a conmparison with depression in elderly patients
without Parkinson’s disease,” International Journal of Geriatric
Psychiatry, vol. 21, no. 3, pp. 252–258, 2006.
[13] K. Miyoshi, A. Ueki, and O. Nagano, “Management of psychi-
atric symptoms of Parkinson’s disease,” European Neurology,
vol. 36, no. 1, pp. 49–54, 1996.
[14] R. Levy and B. Dubois, “Apathy and the functional anatomy of
the prefrontal cortex-basal ganglia circuits,” Cerebral Cortex,
vol. 16, no. 7, pp. 916–928, 2006.
[ 1 5 ]P .T h o m a s ,J .P .C l ´ ement, C. Hazif-Thomas, and J. M.
L´ eger, “Family, Alzheimer’s disease and negative symptoms,”
International Journal of Geriatric Psychiatry,v o l .1 6 ,n o .2 ,p p .
192–202, 2001.
[16] A. Mirakhur, D. Craig, D. J. Hart, S. P. McIlroy, and A.
P. Passmore, “Behavioural and psychological syndromes in
Alzheimer’s disease,” International Journal of Geriatric Psychi-
atry, vol. 19, no. 11, pp. 1035–1039, 2004.
[17] R. van Reekum, D. T. Stuss, and L. Ostrander, “Apathy: why
care?” Journal of Neuropsychiatry and Clinical Neurosciences,
vol. 17, no. 1, pp. 7–19, 2005.
[ 1 8 ]V .C z e r n e c k i ,B .P i l l o n ,J .L .H o u e t o ,J .B .P o c h o n ,R .L e v y ,
and B. Dubois, “Motivation, reward, and Parkinson’s disease:
inﬂuence of dopatherapy,” Neuropsychologia, vol. 40, no. 13,
pp. 2257–2267, 2002.
[ 1 9 ]A .M .L a n d e s ,S .D .S p e r r y ,M .E .S t r a u s s ,a n dD .S .
Geldmacher, “Apathy in Alzheimer’s disease,” Journal of the
American Geriatrics Society, vol. 49, no. 12, pp. 1700–1707,
2001.
[20] J. L. Cummings and D. F. Benson, “Subcortical dementia:
review of an emerging concept,” Archives of Neurology, vol. 41,
no. 8, pp. 874–879, 1984.
[21] L. Kirsch-Darrow, H. F. Fernandez, M. Marsiske, M. S.
Okun, and D. Bowers, “Dissociating apathy and depression in
Parkinson disease,” Neurology, vol. 67, no. 1, pp. 33–38, 2006.
[22] R. S. Marin, R. C. Biedrzycki, and S. Firinciogullari, “Relia-
bility and validity of the apathy evaluation scale,” Psychiatry
Research, vol. 38, no. 2, pp. 143–162, 1991.
[23] O. Kazunori, K. Shotai, A. Kou, N. Suyama, and S. Yamaguchi,
“Assessment of motivational loss in poststroke patients using
the Japanese version of Starkstein’s Apathy scale,” Japanese
Journal of Stroke, vol. 20, no. 3, pp. 318–323, 1998.
[24] P. Sockeel, K. Dujardin, D. Devos, C. Den` eve, A. Dest´ ee, and
L. Defebvre, “The Lille apathy rating scale (LARS), a new
instrument for detecting and quantifying apathy: validation
in Parkinson’s disease,” Journal of Neurology, Neurosurgery and
Psychiatry, vol. 77, no. 5, pp. 579–584, 2006.
[25] E. Mulin, E. Leone, K. Dujardin et al., “Diagnostic criteria for
apathy in clinical practice,” International Journal of Geriatric
Psychiatry, vol. 26, no. 2, pp. 158–165, 2011.
[26] H. Reichmann, M. H. Brecht, J. K¨ oster, P. H. Kraus, and M. R.
Lemke,“Pramipexoleinroutineclinicalpractice:aprospective
observational trial in Parkinson’s disease,” CNS Drugs, vol. 17,
no. 13, pp. 965–973, 2003.
[27] G. C. Pluck and R. G. Brown, “Apathy in Parkinson’s disease,”
Journal of Neurology Neurosurgery and Psychiatry, vol. 73, no.
6, pp. 636–642, 2002.
[28] R. P. Snaith, M. Hamilton, S. Morley, A. Humayan, D. Har-
greaves, and P. Trigwell, “A scale for the assessment of hedonic
tone. The Snaith-Hamilton Pleasure Scale,” British Journal of
Psychiatry, vol. 167, no. 1, pp. 99–103, 1995.
[29] I. Rectorova, I. Rektor, M. Bares et al., “Pramipexole and
pergolide in the treatment of depression in Parkinson’s
disease:anationalmulticentreprospectiverandomizedstudy,”
European Journal of Neurology, vol. 10, no. 4, pp. 399–406,
2003.
[30] M. Yokochi, “Mesolimbic and mesocortical pathways in
Parkinson disease,” Brain and Nerve, vol. 59, no. 9, pp. 943–
951, 2007.
[31] P. Bxarone, W. Poewe, S. Albrecht et al., “Pramipexole for the
treatmentofdepressivesymptomsinpatientswithParkinson’s
disease:arandomised,double-blind,placebo-controlledtrial,”
The Lancet Neurology, vol. 9, no. 6, pp. 573–580, 2010.
[32] T. Tom and J. L. Cummings, “Depression in Parkinson’s
disease.Pharmacologicalcharacteristicsandtreatment,”Drugs
and Aging, vol. 12, no. 1, pp. 55–74, 1998.
[33] G. P. Reynolds, P. Riederer, M. Sandler, K. Jellinger, and D.
Seemann, “Amphetamine and 2-phenylethylamine in post-
mortem Parkinsonian brain after (-)deprenyl administration,”
Journal of Neural Transmission, vol. 43, no. 3-4, pp. 271–277,
1978.
[34] H. Reichmann, “Diagnosis and therapy of idiopathic Parkin-
son’s disease,” MMW-Fortschritte der Medizin, vol. 2, no. 54,
pp. 56–58, 2006.
[35] J. Andersen, E. Aabro, N. Gulmann, A. Hjelmsted, and H. E.
Pedersen, “Anti-depressive treatment in Parkinson’s disease. A
controlled trial of the eﬀect of nortriptyline in patients with
Parkinson’s disease treated with L-dopa,” Acta Neurologica
Scandinavica, vol. 62, no. 4, pp. 210–219, 1980.
[36] R. A. Hauser and T. A. Zesiewicz, “Sertraline for the treatment
ofdepressioninParkinson’sdisease,” MovementDisorders,vol.
12, no. 5, pp. 756–759, 1997.
[37] R. Ceravolo, A. Nuti, A. Piccinni et al., “Paroxetine in Parkin-
son’s disease: eﬀects on motor and depressive symptoms,”
Neurology, vol. 55, no. 8, pp. 1216–1218, 2000.ISRN Neurology 9
[38] J. M. Miyasaki, K. Shannon, V. Voon et al., “Practice param-
eter: evaluation and treatment of depression, psychosis, and
dementia in Parkinson disease (an evidence-based review):
report of the Quality Standards Subcommittee of the Ameri-
canAcademyofNeurology,” Neurology,vol.66,no.7,pp.996–
1002, 2006.
[ 3 9 ]W .J .B a r n h a r t ,E .H .M a k e l a ,a n dM .J .L a t o c h a ,“ S S R I -
induced apathy syndrome: a clinical review,” Journal of
Psychiatric Practice, vol. 10, no. 3, pp. 196–199, 2004.
[40] T. Maruyama, “New treatment of depression in Parkinson’s
disease,” International Journal of Psychiatry in Clinical Practice,
vol. 7, no. 1, pp. 25–27, 2003.
[41] H. Takahashi, M. Kamata, K. Yoshida, H. Higuchi, and T.
Shimizu, “Remarkable eﬀect of milnacipran, a serotonin-
noradrenalin reuptake inhibitor (SNRI), on depressive symp-
tomsinpatientswithParkinson’sdiseasewhohaveinsuﬃcient
response to selective serotonin reuptake inhibitors (SSRIs):
two case reports,” Progress in Neuro-Psychopharmacology and
Biological Psychiatry, vol. 29, no. 2, pp. 351–353, 2005.
[42] H.-J. M¨ oller, “Are all antidepressants the same?” Journal of
Clinical Psychiatry, vol. 61, supplement 6, pp. 24–28, 2000.